X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Value assessment should include all aspects of value that matter to patients

By Emilie Signora  |    August 10, 2022
We need to move toward a more value-driven health care system that centers around patients’ needs. Sound evidence can help guide us toward that, and we’re committed to developing tools to help...   Read More

You won’t fix what you don’t value: Two reasons why traditional cost-effective analyses can perpetuate health inequities

By Jackie McRae  |    June 16, 2022
A new report from Partnership for Health Analytic Research or PHAR describes how value assessments that use traditional cost-effectiveness analyses can overlook important health disparities and risk...   Read More

PhRMA presents research at ISPOR 2022

By Jackie McRae  |    May 26, 2022
Last week at the ISPOR annual international meeting, PhRMA partnered with multiple organizations committed to advancing value assessment research and methods. We worked with a range of academics,...   Read More

Creating a new patient risk paradigm in American health care

By Guest Contributor  |    May 18, 2021
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Panel releases best practices in cost-effectiveness analysis

By Lauren Neves  |    October 3, 2016
Recently, the Journal of the American Medical Association (JAMA) published findings and recommendations from the Second Panel on Cost-Effectiveness in Health and Medicine, detailing what the authors...   Read More

Who gets a seat at ICER’s table? Hint: It’s not patients

By Holly Campbell  |    September 19, 2016
As we continue the move toward a value-driven health care system, efforts to develop tools supporting patient decision-making will play a central role. These tools, including emerging value...   Read More

ICER puts hard-fought progress in non-small cell lung cancer treatment at risk

By Holly Campbell  |    September 1, 2016
Lung cancer is the leading cause of cancer death among men and women in the United States, and each year, tens of thousands of Americans are diagnosed with the most common form, non-small cell lung...   Read More

What they are saying about ICER’s scoping document for non-small cell lung cancer

By Holly Campbell  |    July 11, 2016
The Institute for Clinical and Economic Review (ICER) has set its sights on a new target: life-saving treatments for advanced non-small cell lung cancer (NSCLC). ICER’s latest draft scoping document...   Read More

ICER framework threatens to halt continued progress against multiple myeloma

By Holly Campbell  |    May 26, 2016
Progress in the fight against multiple myeloma, a cancer of the blood and bone marrow, has been nothing short of remarkable. Just a decade ago, patients diagnosed faced a poor prognosis and treatment...   Read More

New academic initiative aims to inform approaches to value assessment frameworks

By Holly Campbell  |    May 13, 2016
As the U. S. health care market continues to shift toward a system that prioritizes and rewards value, there is increasing attention on the development and use of value assessment frameworks. When...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates